How to manage the initiation of apomorphine therapy without antiemetic pretreatment: A review of the literature

INTRODUCTION: Pretreatment with the antiemetic trimethobenzamide has been recommended practice in the United States (US) to address the risk of nausea and vomiting during initiation of apomorphine treatment. However, trimethobenzamide is no longer being manufactured in the US, and despite the recent...

Descripción completa

Detalles Bibliográficos
Autores principales: Isaacson, Stuart H., Dewey, Richard B., Pahwa, Rajesh, Kremens, Daniel E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9860403/
https://www.ncbi.nlm.nih.gov/pubmed/36691604
http://dx.doi.org/10.1016/j.prdoa.2022.100174

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9860403/
https://www.ncbi.nlm.nih.gov/pubmed/36691604
http://dx.doi.org/10.1016/j.prdoa.2022.100174

Ejemplares similares